Form 4: Stoke Therapeutics Director Receives Stock Option Grant

Director Arthur A. Levin was granted 17,786 stock options in Stoke Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Arthur A. Levin received a grant of 17,786 stock options on June 3, 2026.
• The options have an exercise price of $29.46 per share.
• The options are set to expire on June 2, 2036.
• The grant vests in full on the earlier of June 3, 2027, or the date of the next annual stockholder meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of the company's common stock.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors in mid-cap biotechnology firms.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 3, 2027, or the next annual meeting.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Trading, Stock Options, Director Compensation